JP7793284B2 - 高活性ｎｋ細胞の処理方法 - Google Patents

高活性ｎｋ細胞の処理方法

Info

Publication number
JP7793284B2
JP7793284B2 JP2020035297A JP2020035297A JP7793284B2 JP 7793284 B2 JP7793284 B2 JP 7793284B2 JP 2020035297 A JP2020035297 A JP 2020035297A JP 2020035297 A JP2020035297 A JP 2020035297A JP 7793284 B2 JP7793284 B2 JP 7793284B2
Authority
JP
Japan
Prior art keywords
cells
solvent
hours
thawing
suspended
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020035297A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021136883A (ja
JP2021136883A5 (https=
Inventor
結 原田
吉和 米満
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gaia Biomedicine Inc
Original Assignee
Gaia Biomedicine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2020035297A priority Critical patent/JP7793284B2/ja
Application filed by Gaia Biomedicine Inc filed Critical Gaia Biomedicine Inc
Priority to EP21765044.9A priority patent/EP4151717A4/en
Priority to CN202180018428.7A priority patent/CN115279887A/zh
Priority to US17/908,472 priority patent/US20230109717A1/en
Priority to KR1020227033295A priority patent/KR20220148233A/ko
Priority to PCT/JP2021/007863 priority patent/WO2021177279A1/ja
Priority to AU2021230860A priority patent/AU2021230860A1/en
Priority to TW110107331A priority patent/TW202140770A/zh
Publication of JP2021136883A publication Critical patent/JP2021136883A/ja
Publication of JP2021136883A5 publication Critical patent/JP2021136883A5/ja
Priority to JP2023120214A priority patent/JP2023126695A/ja
Application granted granted Critical
Publication of JP7793284B2 publication Critical patent/JP7793284B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/12—Chemical aspects of preservation
    • A01N1/122—Preservation or perfusion media
    • A01N1/125—Freeze protecting agents, e.g. cryoprotectants or osmolarity regulators
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/16—Physical preservation processes
    • A01N1/162—Temperature processes, e.g. following predefined temperature changes over time
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/04—Preserving or maintaining viable microorganisms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Environmental Sciences (AREA)
  • Dentistry (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
JP2020035297A 2020-03-02 2020-03-02 高活性ｎｋ細胞の処理方法 Active JP7793284B2 (ja)

Priority Applications (9)

Application Number Priority Date Filing Date Title
JP2020035297A JP7793284B2 (ja) 2020-03-02 2020-03-02 高活性ｎｋ細胞の処理方法
TW110107331A TW202140770A (zh) 2020-03-02 2021-03-02 高活性nk細胞之處理方法
US17/908,472 US20230109717A1 (en) 2020-03-02 2021-03-02 Method for treating highly active nk cells
KR1020227033295A KR20220148233A (ko) 2020-03-02 2021-03-02 고활성 nk 세포의 처리 방법
PCT/JP2021/007863 WO2021177279A1 (ja) 2020-03-02 2021-03-02 高活性ｎｋ細胞の処理方法
AU2021230860A AU2021230860A1 (en) 2020-03-02 2021-03-02 Method for treating highly active NK cells
EP21765044.9A EP4151717A4 (en) 2020-03-02 2021-03-02 Method for treating highly active nk cells
CN202180018428.7A CN115279887A (zh) 2020-03-02 2021-03-02 高活性nk细胞的处理方法
JP2023120214A JP2023126695A (ja) 2020-03-02 2023-07-24 高活性ｎｋ細胞の処理方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2020035297A JP7793284B2 (ja) 2020-03-02 2020-03-02 高活性ｎｋ細胞の処理方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023120214A Division JP2023126695A (ja) 2020-03-02 2023-07-24 高活性ｎｋ細胞の処理方法

Publications (3)

Publication Number Publication Date
JP2021136883A JP2021136883A (ja) 2021-09-16
JP2021136883A5 JP2021136883A5 (https=) 2022-08-29
JP7793284B2 true JP7793284B2 (ja) 2026-01-05

Family

ID=77614337

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020035297A Active JP7793284B2 (ja) 2020-03-02 2020-03-02 高活性ｎｋ細胞の処理方法
JP2023120214A Pending JP2023126695A (ja) 2020-03-02 2023-07-24 高活性ｎｋ細胞の処理方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023120214A Pending JP2023126695A (ja) 2020-03-02 2023-07-24 高活性ｎｋ細胞の処理方法

Country Status (8)

Country Link
US (1) US20230109717A1 (https=)
EP (1) EP4151717A4 (https=)
JP (2) JP7793284B2 (https=)
KR (1) KR20220148233A (https=)
CN (1) CN115279887A (https=)
AU (1) AU2021230860A1 (https=)
TW (1) TW202140770A (https=)
WO (1) WO2021177279A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240063899A (ko) * 2021-09-08 2024-05-10 가부시키가이샤 가이아바이오메디신 세포의 처리 방법
EP4582545A1 (en) 2022-08-30 2025-07-09 GAIA BioMedicine Inc. Monobody and nk cells
AU2024234571A1 (en) 2023-03-15 2025-09-25 Gaia Biomedicine Inc. Solution for suspending cells and use thereof
KR102940135B1 (ko) 2024-01-05 2026-03-16 인하대학교 산학협력단 고삼투 및 진동 자극에 노출된 배양보조세포를 통한 nk 세포의 효과적인 활성화 및 이의 용도
CN121294344A (zh) * 2024-06-20 2026-01-09 杭州百瑞竞康生物技术有限公司 Nk细胞无血清培养基

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013532469A (ja) 2010-07-13 2013-08-19 アントフロゲネシス コーポレーション ナチュラルキラー細胞を生成させる方法
WO2018202853A1 (en) 2017-05-04 2018-11-08 Mesoblast International Sàrl Mesenchymal lineage precursor or stem cells with enhanced immunosuppression
JP2018535666A (ja) 2015-10-15 2018-12-06 セルラリティ インコーポレイテッド ナチュラルキラー細胞およびｉｌｃ３細胞ならびにそれらの使用
JP2019024418A (ja) 2017-07-31 2019-02-21 公立大学法人大阪府立大学 選択分離用培地
JP2019050824A (ja) 2012-11-29 2019-04-04 タカラ バイオ ヨーロッパ アーベー 哺乳類多能性幹細胞由来の内胚葉細胞を産生するための改良された方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4385158B2 (ja) * 2000-12-04 2009-12-16 株式会社リンフォテック 細胞の保存液および該保存液を用いた細胞の保存方法
JP4947948B2 (ja) 2004-10-12 2012-06-06 ニプロ株式会社 細胞保存液
US20120149108A1 (en) 2009-08-19 2012-06-14 Masashige Tanabe Cell preservation method
WO2016122014A1 (ko) * 2015-01-27 2016-08-04 한국생명공학연구원 자연살해세포의 대량생산 방법 및 상기 방법으로 수득된 자연살해세포의 항암제로서의 용도
WO2018017843A1 (en) * 2016-07-22 2018-01-25 Tissue Testing Technologies Llc Enhancement of cell cryopreservation with glycolipids
JP6647240B2 (ja) 2017-05-12 2020-02-14 米満　吉和 高活性ｎｋ細胞、およびその利用
JP6543375B1 (ja) 2018-03-27 2019-07-10 株式会社ガイアバイオメディシン ケモカインレセプターと細胞接着分子を発現するｃｄ３陰性細胞の集団、およびその利用
CN114615886A (zh) * 2019-08-29 2022-06-10 得克萨斯大学体系董事会 细胞冷冻保存培养基

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013532469A (ja) 2010-07-13 2013-08-19 アントフロゲネシス コーポレーション ナチュラルキラー細胞を生成させる方法
JP2019050824A (ja) 2012-11-29 2019-04-04 タカラ バイオ ヨーロッパ アーベー 哺乳類多能性幹細胞由来の内胚葉細胞を産生するための改良された方法
JP2018535666A (ja) 2015-10-15 2018-12-06 セルラリティ インコーポレイテッド ナチュラルキラー細胞およびｉｌｃ３細胞ならびにそれらの使用
WO2018202853A1 (en) 2017-05-04 2018-11-08 Mesoblast International Sàrl Mesenchymal lineage precursor or stem cells with enhanced immunosuppression
JP2019024418A (ja) 2017-07-31 2019-02-21 公立大学法人大阪府立大学 選択分離用培地

Also Published As

Publication number Publication date
JP2023126695A (ja) 2023-09-07
JP2021136883A (ja) 2021-09-16
TW202140770A (zh) 2021-11-01
KR20220148233A (ko) 2022-11-04
WO2021177279A1 (ja) 2021-09-10
CN115279887A (zh) 2022-11-01
US20230109717A1 (en) 2023-04-13
EP4151717A1 (en) 2023-03-22
EP4151717A4 (en) 2024-04-17
AU2021230860A1 (en) 2022-09-22

Similar Documents

Publication Publication Date Title
JP7793284B2 (ja) 高活性ｎｋ細胞の処理方法
JP2025156345A (ja) 免疫療法のためのｎｋ細胞組成物および調製物ならびにそれらの製造のための方法
EP3000876B1 (en) Method for preparing nk cells
JP2022088551A (ja) 増殖造血幹細胞／前駆細胞集団の利用
AU2016297523B2 (en) Methods and compositions for stem cell transplantation
JP7144872B2 (ja) ヒトリンパ球細胞培養用無血清培地
WO2014110020A1 (en) Compositions and methods for expansion of embryonic hematopoietic stem cells
JP2025038215A (ja) Ｍｒｎａの増幅のための方法及び組成物
Karvouni et al. Challenges in αCD38-chimeric antigen receptor (CAR)-expressing natural killer (NK) cell-based immunotherapy in multiple myeloma: Harnessing the CD38dim phenotype of cytokine-stimulated NK cells as a strategy to prevent fratricide
EP4400576A1 (en) Method for treating cells
Migliaccio et al. Under HEMA conditions, self-replication of human erythroblasts is limited by autophagic death
TW202430631A (zh) 產生γδＴ細胞之方法
HK40083554A (en) Method for treating highly active nk cells
HK40084673A (en) Method for treating highly active nk cells
US12091684B2 (en) Platelet-derived mitochondria treatment and method of generating multipotent cells
KR20250161543A (ko) 세포를 현탁하기 위한 액 및 그 이용
HK40108875A (en) Method for treating cells
WO2020251046A1 (ja) 医薬組成物
Córdoba-Espejo et al. GMP-compliant manufacturing of allogeneic peripheral blood CAR-NK cells for the treatment of acute myeloid leukemia
US20220233676A1 (en) Formulations of activating antigen carriers
Landum Targeting a bicarbonate transporter in pancreatic cancer overcomes immunosuppression
WO2026062399A1 (en) Granulocytes and granulocyte precursors
KR20220020277A (ko) 확장된 줄기 세포 생성물을 사용하여 혈액 악성종양을 갖는 환자에 대한 치료 결과를 개선시키기 위한 조성물 및 방법
HK1185099A (en) Methods of generating natural killer cells

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220728

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220728

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20220728

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220819

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220823

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221024

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221104

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221129

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230327

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230425

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230724

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230831

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230901

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20230929

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20250628

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20250701

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251017

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251217

R150 Certificate of patent or registration of utility model

Ref document number: 7793284

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150